Roth Capital Resumes Coverage on RXi Pharmaceuticals (RXII) at Buy
Tweet
Share
E-mailGet Alerts RXII Hot Sheet
Price: $0.33 --0%
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Roth Capital resumes coverage on RXi Pharmaceuticals (NASDAQ: RXII) with a Buy. PT $5.
For more ratings news on RXi Pharmaceuticals click here and for the rating history of RXi Pharmaceuticals click here.
Shares of RXi Pharmaceuticals closed at $1.30 yesterday.
For more ratings news on RXi Pharmaceuticals click here and for the rating history of RXi Pharmaceuticals click here.
Shares of RXi Pharmaceuticals closed at $1.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scotiabank Starts Qualys (QLYS) at Sector Perform
- Victoria's Secret (VSCO) initiated with sell rating at Goldman Sachs on 'less attractive' risk/reward
- Bernstein SocGen Group Starts General Motors (GM) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
